Sign in
Not yet taking people in AustriaPhase 2

Scan with a radioactive tracer for pancreatic and lobular breast cancer

Tests how well a HKG301 PET/CT scan detects pancreatic and lobular breast cancer.

Key facts

Who runs it
Gemeinnuetzige Salzburger Landeskliniken Betriebsgesellschaft mbH
Where
Salzburg, AustriaSee the site
Registry title
[⁶⁸Ga]Ga-HKG301(FAP-2286) PET/CT in pancreatic and breast malignancies
Status
Not yet recruiting
Phase
Phase 2
People taking part
60 people, planned
Started
15 Jul 2026
Expected to end
15 Jul 2029
Type of study
Interventional
Record updated
1 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with pancreatic cancer (PDAC) that can be removed by surgery, and women with invasive lobular breast cancer. They will have a [⁶⁸Ga]Ga-HKG301 PET/CT scan.

Age
18 years or older
Sex
Pancreatic cancer group: all sexes. Breast cancer group: women only.
Disease stage
Pancreatic group: suspected or proven PDAC with a tumor that can be removed by surgery, and CA19-9 above 500 U/mL and/or unclear results on regular imaging. Breast group: proven invasive lobular breast cancer with HER2-positive or ER below 10%, or clinical stage II (≥ cT2) or stage III.
Earlier treatment
People must have had, or be scheduled for, standard first staging with ceCT, MRI and [¹⁸F]FDG PET/CT.
Biomarker or test result
Pancreatic group: serum CA19-9 above 500 U/mL (or unclear findings on conventional imaging). Breast group: HER2-positive or ER below 10% (unless stage II or III).

Main reasons for not taking part

  • Pregnancy or breastfeeding
  • Creatinine clearance below 60 mL/min (CKD-EPI)
  • Known allergy to radiotracers or to HKG301
  • Cannot have a PET/CT scan (for example severe claustrophobia or cannot lie still)
  • Health, mental or social conditions that make consent or following the trial difficult

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Adults (≥18 years) with suspicion of and/or histopathology-proven PDAC with primarily resectable tumor and serum CA19-9 levels > 500 U/mL and/or inconclusive findings on conventional imaging
  • Female adults (≥18 years) with histopathology-proven invasive lobular breast cancer patients with unfavorable receptor status (any stage with HER2-positive or ER < 10%) or with clinical stage II (≥ cT2) or stage III disease
  • Patients who have undergone or are scheduled for standard initial staging with ceCT, MRI, and [¹⁸F]FDG PET/CT
  • Patients who gave free written consent to participate in the clinical trial through the Informed Consent Form
  • Patients willing to comply with all clinical trial procedures and show availability for the duration of the clinical trial
  • Patients with an ECOG performance status ≤ 2

Who cannot take part

  • Medical or psychiatric conditions that compromise the patient’s ability to give informed consent
  • Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the clinical trial protocol and follow-up schedule
  • Known hypersensitivity to radiotracers, or compounds of HKG301
  • Significantly impaired renal function (creatinine clearance < 60 mL/min according to CKD-EPI)
  • Pregnancy or breastfeeding
  • Inability to undergo PET/CT scanning (e.g., severe claustrophobia, weight limits or inability to tolerate lying for the duration of a PET/CT scan)

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you pregnant or breastfeeding?

Where in Austria

  • Gemeinnuetzige Salzburger Landeskliniken Betriebsgesellschaft mbHSalzburg, AustriaNot yet recruiting

About the trial

What the trial wants to find out

To assess diagnostic performance of HKG301 PET/CT in patients with Pancreatic adenocarcinoma (PDAC) and to assess diagnostic performance of HKG301 PET/CT in patients with lobular breast cancer.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
Diagnostic Performance of [⁶⁸Ga]Ga-HKG301 (FAP-2286) PET/CT in Biologic Borderline Resectable Pancreatic and Invasive Lobular Breast Cancers – FAPTRACE Trial
Plain-language title
Scan with a radioactive tracer for pancreatic and lobular breast cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Fit questions
Built from 2026-526498-40-00, who can take part
Record updated
1 November 2026